Neurology – Featured
Join Mayo Clinic Laboratories and C2N Diagnostics for our webinar exploring how the evolution of blood biomarker testing for Alzheimer's disease has expanded access to earlier, less-invasive diagnosis. Focusing on the newly FDA-cleared PrecivityAD2 blood test, which is offered by Mayo Clinic Laboratories in collaboration with C2N Diagnostics, the discussion will highlight how results from blood biomarker testing can support timely diagnosis, informed clinical decision-making, and improved patient care.
Collaborating with Mayo Clinic Laboratories, UNC Health streamlined neuroimmunology test ordering — eliminating outmoded testing and elevating diagnostic accuracy.
Learn more about how Mayo Clinic’s Nerve Pathology Laboratory leverages decades of nerve pathology testing experience and unmatched clinical expertise to provide diagnostic clarity for rare and complex neuropathies.
Find out how our suite of autoimmune movement disorder testing can help diagnose PDE10A autoimmunity in patients who present with hyperkinetic movement disorders.
Genome-wide methylation profiling is transforming the way clinicians approach brain tumor diagnosis. By analyzing epigenetic patterns across the genome, this advanced testing method provides a new level of precision, helping resolve ambiguous cases, reduce diagnostic variability, and support more confident clinical decision-making in complex CNS tumors.
Discover how Mayo Clinic’s nationally recognized Muscle Pathology Laboratory provides unparalleled diagnostic accuracy for rare muscle diseases through decades of experience, specialized testing, and integrated clinical-pathological evaluation.
Learn how our autoimmune/paraneoplastic evaluation for encephalopathy uses CSF testing to confirm an autoimmune GFAP meningoencephalomyelitis diagnosis.
Autoimmune neurology testing has evolved beyond limited paraneoplastic evaluations to phenotype-specific panels that identify clinically relevant antibodies. This phenotype-specific approach significantly improves diagnostic accuracy, reduces false positives, and helps guide faster, more personalized treatment for complex neurological diseases.
Learn more about our CNS demyelinating disease testing through this case study focused on MOG-IgG as a marker of acute disseminated encephalomyelitis.
Mayo Clinic Laboratories’ MS testing cascade, which starts with kappa free light chain (KFLC) testing and reflexes to oligoclonal banding when indicated, is supported by the revised 2024 McDonald Criteria. This approach delivers faster, more definitive results, enabling earlier treatment decisions and improved patient outcomes.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to explore recent examples of diagnostic innovations that are improving patient care. Dr. Pritt also welcomes Matthew Schultz, Ph.D., a clinical biochemical geneticist at Mayo Clinic, to discuss how a novel test is delivering answers for patients with a recently identified peripheral neuropathy.
This presentation offers a clear introduction to emerging blood based biomarkers for Alzheimer’s disease.
In this video, Dr. Vijay Ramanan shares perspectives on rational approaches to testing in the cognitive neurology, mild cognitive impairment, and dementia settings.